{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T05:30:54Z","timestamp":1744867854739},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T00:00:00Z","timestamp":1649808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T00:00:00Z","timestamp":1649808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00115-022-01288-0","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T17:07:43Z","timestamp":1649869663000},"page":"557-565","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gentherapieoptionen der heredit\u00e4ren Transthyretinamyloidose"],"prefix":"10.1007","volume":"93","author":[{"given":"Matthias","family":"Schilling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,13]]},"reference":[{"issue":"1","key":"1288_CR1","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","volume":"29","author":"D Adams","year":"2016","unstructured":"Adams\u00a0D, Suhr\u00a0OB, Hund\u00a0E, Obici\u00a0L, Tournev\u00a0I, Campistol\u00a0JM, Slama\u00a0MS, Hazenberg\u00a0BP, Coelho\u00a0T (2016) First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol 29(1):S14\u201326","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"1288_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams\u00a0D, Gonzalez-Duarte\u00a0A, O\u2019Riordan\u00a0WD, Yang\u00a0CC, Ueda\u00a0M, Kristen\u00a0AV, Tournev\u00a0I, Schmidt\u00a0HH, Coelho\u00a0T, Berk\u00a0JL, Lin\u00a0KP, Vita\u00a0G, Attarian\u00a0S, Plante-Bordeneuve\u00a0V, Mezei\u00a0MM, Campistol\u00a0JM, Buades\u00a0J, Brannagan\u00a0TH 3rd, Kim\u00a0BJ, Oh\u00a0J, Parman\u00a0Y, Sekijima\u00a0Y, Hawkins\u00a0PN, Solomon\u00a0SD, Polydefkis\u00a0M, Dyck\u00a0PJ, Gandhi\u00a0PJ, Goyal\u00a0S, Chen\u00a0J, Strahs\u00a0AL, Nochur\u00a0SV, Sweetser\u00a0MT, Garg\u00a0PP, Vaishnaw\u00a0AK, Gollob\u00a0JA, Suhr\u00a0OB (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N\u00a0Engl J Med 379(1):11\u201321","journal-title":"N Engl J Med"},{"issue":"3","key":"1288_CR3","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/brain\/75.3.408","volume":"75","author":"C Andrade","year":"1952","unstructured":"Andrade\u00a0C (1952) A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 75(3):408\u2013427","journal-title":"Brain"},{"issue":"1","key":"1288_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson\u00a0MD, Waddington-Cruz\u00a0M, Berk\u00a0JL, Polydefkis\u00a0M, Dyck\u00a0PJ, Wang\u00a0AK, Plante-Bordeneuve\u00a0V, Barroso\u00a0FA, Merlini\u00a0G, Obici\u00a0L, Scheinberg\u00a0M, Brannagan\u00a0TH 3rd, Litchy\u00a0WJ, Whelan\u00a0C, Drachman\u00a0BM, Adams\u00a0D, Heitner\u00a0SB, Conceicao\u00a0I, Schmidt\u00a0HH, Vita\u00a0G, Campistol\u00a0JM, Gamez\u00a0J, Gorevic\u00a0PD, Gane\u00a0E, Shah\u00a0AM, Solomon\u00a0SD, Monia\u00a0BP, Hughes\u00a0SG, Kwoh\u00a0TJ, McEvoy\u00a0BW, Jung\u00a0SW, Baker\u00a0BF, Ackermann\u00a0EJ, Gertz\u00a0MA, Coelho\u00a0T (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N\u00a0Engl J Med 379(1):22\u201331","journal-title":"N Engl J Med"},{"issue":"24","key":"1288_CR5","doi-asserted-by":"publisher","first-page":"9629","DOI":"10.1073\/pnas.1121005109","volume":"109","author":"CE Bulawa","year":"2012","unstructured":"Bulawa\u00a0CE, Connelly\u00a0S, Devit\u00a0M, Wang\u00a0L, Weigel\u00a0C, Fleming\u00a0JA, Packman\u00a0J, Powers\u00a0ET, Wiseman\u00a0RL, Foss\u00a0TR, Wilson\u00a0IA, Kelly\u00a0JW, Labaudini\u00e8re\u00a0R (2012) Tafamidis, a\u00a0potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S\u00a0A 109(24):9629\u20139634","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1288_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1056\/NEJMe1805499","volume":"379","author":"JN Buxbaum","year":"2018","unstructured":"Buxbaum\u00a0JN (2018) Oligonucleotide drugs for transthyretin amyloidosis. N\u00a0Engl J Med 379(1):82\u201385","journal-title":"N Engl J Med"},{"issue":"8","key":"1288_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho\u00a0T, Maia\u00a0LF, Martins da Silva\u00a0A, Waddington Cruz\u00a0M, Plante-Bordeneuve\u00a0V, Lozeron\u00a0P, Suhr\u00a0OB, Campistol\u00a0JM, Conceicao\u00a0IM, Schmidt\u00a0HH, Trigo\u00a0P, Kelly\u00a0JW, Labaudiniere\u00a0R, Chan\u00a0J, Packman\u00a0J, Wilson\u00a0A, Grogan\u00a0DR (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a\u00a0randomized, controlled trial. Neurology 79(8):785\u2013792","journal-title":"Neurology"},{"issue":"1","key":"1288_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/mus.20644","volume":"35","author":"I Concei\u00e7\u00e3o","year":"2007","unstructured":"Concei\u00e7\u00e3o\u00a0I, De Carvalho\u00a0M (2007) Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve 35(1):116\u2013118","journal-title":"Muscle Nerve"},{"issue":"1","key":"1288_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jns.12153","volume":"21","author":"I Concei\u00e7\u00e3o","year":"2016","unstructured":"Concei\u00e7\u00e3o\u00a0I, Gonz\u00e1lez-Duarte\u00a0A, Obici\u00a0L, Schmidt\u00a0HH, Simoneau\u00a0D, Ong\u00a0ML, Amass\u00a0L (2016) \u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy. J\u00a0Peripher Nerv Syst 21(1):5\u20139","journal-title":"J Peripher Nerv Syst"},{"key":"1288_CR10","unstructured":"Coutinho P, Lazaro da Silva A, Lopes Lima J, Resende Barbosa A (1980) Forty years of experience with type I amyloid neuropathy. Review of 483\u00a0cases. Amyloid Amyloidosis: 88\u201398"},{"issue":"10","key":"1288_CR11","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1007\/s00415-020-09962-6","volume":"268","author":"MF Dohrn","year":"2021","unstructured":"Dohrn\u00a0MF, Auer-Grumbach\u00a0M, Baron\u00a0R, Birklein\u00a0F, Escolano-Lozano\u00a0F, Geber\u00a0C, Grether\u00a0N, Hagenacker\u00a0T, Hund\u00a0E, Sachau\u00a0J, Schilling\u00a0M, Schmidt\u00a0J, Schulte-Mattler\u00a0W, Sommer\u00a0C, Weiler\u00a0M, Wunderlich\u00a0G, Hahn\u00a0K (2021) Chance or challenge, spoilt for choice? New recommendations on diagnostic and therapeutic considerations in hereditary transthyretin amyloidosis with polyneuropathy: the German\/Austrian position and review of the literature. J\u00a0Neurol 268(10):3610\u20133625","journal-title":"J Neurol"},{"key":"1288_CR12","unstructured":"Swedish Orphan Biovitrum GmbH (2022) Fachinformation Inotersen. https:\/\/sobi-deutschland.de\/produkte\/tegsedi. Zugegriffen: 05.04.2022"},{"issue":"9","key":"1288_CR13","doi-asserted-by":"publisher","first-page":"e01371","DOI":"10.1002\/brb3.1371","volume":"9","author":"MA Gertz","year":"2019","unstructured":"Gertz\u00a0MA, Mauermann\u00a0ML, Grogan\u00a0M, Coelho\u00a0T (2019) Advances in the treatment of hereditary transthyretin amyloidosis: a review. Brain Behav 9(9):e1371","journal-title":"Brain Behav"},{"issue":"08","key":"1288_CR14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1055\/a-0649-0724","volume":"45","author":"E Hund","year":"2018","unstructured":"Hund\u00a0E, Kristen\u00a0AV, Auer-Grumbach\u00a0M, Geber\u00a0C, Birklein\u00a0F, Schulte-Mattler\u00a0W, Sommer\u00a0C, Schmidt\u00a0H, R\u00f6cken\u00a0C (2018) Transthyretin-Amyloidose (ATTR-Amyloidose): Empfehlungen zum Management in Deutschland und \u00d6sterreich. Akt Neurol 45(08):605\u2013616","journal-title":"Akt Neurol"},{"issue":"3","key":"1288_CR15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1399-0004.1991.tb03085.x","volume":"40","author":"G Holmgren","year":"1991","unstructured":"Holmgren\u00a0G, Steen\u00a0L, Ekstedt\u00a0J, Groth\u00a0CG, Ericzon\u00a0BG, Eriksson\u00a0S, Andersen\u00a0O, Karlberg\u00a0I, Nord\u00e9n\u00a0G, Nakazato\u00a0M et al (1991) Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 40(3):242\u2013246","journal-title":"Clin Genet"},{"key":"1288_CR16","unstructured":"Bundesministerium f\u00fcr Gesundheit (2022) Informationen zum Coronavirus. https:\/\/www.bundesgesundheitsministerium.de. Zugegriffen: 14. Febr. 2022"},{"key":"1288_CR17","unstructured":"Alnylam Pharmaceuticals (2022) Alnylam is the leading RNAi therapeutics company. https:\/\/www.alnylam.com. Zugegriffen: 14. Febr. 2022"},{"key":"1288_CR18","unstructured":"ClinicalTrials.gov (2022) Webpr\u00e4senz. https:\/\/clinicaltrials.gov. Zugegriffen: 14. Febr. 2022"},{"key":"1288_CR19","unstructured":"Ionis Pharmaceuticals (2022) Eplontersen. https:\/\/www.ionispharma.com\/medicines\/akcea-ttr-l. Zugegriffen: 14. Febr. 2022"},{"key":"1288_CR20","unstructured":"BioNews, Inc. (2022) Rare TTR gene mutation detected in three Japanese patients with FAP. https:\/\/fapnewstoday.com. Zugegriffen: 4. M\u00e4rz 2022"},{"issue":"3\u20134","key":"1288_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000490553","volume":"51","author":"M In\u00eas","year":"2018","unstructured":"In\u00eas\u00a0M, Coelho\u00a0T, Concei\u00e7\u00e3o\u00a0I, Duarte-Ramos\u00a0F, de Carvalho\u00a0M, Costa\u00a0J (2018) Epidemiology of transthyretin familial amyloid polyneuropathy in Portugal: a nationwide study. Neuroepidemiology 51(3\u20134):177\u2013182","journal-title":"Neuroepidemiology"},{"issue":"6","key":"1288_CR22","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini\u00a0G, Bellotti\u00a0V (2003) Molecular mechanisms of amyloidosis. N\u00a0Engl J Med 349(6):583\u2013596","journal-title":"N Engl J Med"},{"issue":"3","key":"1288_CR23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/13506129.2020.1730790","volume":"27","author":"L Obici","year":"2020","unstructured":"Obici\u00a0L, Berk\u00a0JL, Gonz\u00e1lez-Duarte\u00a0A, Coelho\u00a0T, Gillmore\u00a0J, Schmidt\u00a0HH, Schilling\u00a0M, Yamashita\u00a0T, Labeyrie\u00a0C, Brannagan\u00a0TH 3rd, Ajroud-Driss\u00a0S, Gorevic\u00a0P, Kristen\u00a0AV, Franklin\u00a0J, Chen\u00a0J, Sweetser\u00a0MT, Wang\u00a0JJ, Adams\u00a0D (2020) Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Amyloid 27(3):153\u2013162","journal-title":"Amyloid"},{"issue":"1","key":"1288_CR24","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/WCO.0000000000000288","volume":"29","author":"Y Parman","year":"2016","unstructured":"Parman\u00a0Y, Adams\u00a0D, Obici\u00a0L, Galan\u00a0L, Guergueltcheva\u00a0V, Suhr\u00a0OB et al (2016) Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol 29(1):S3\u2013S13","journal-title":"Curr Opin Neurol"},{"issue":"29","key":"1288_CR25","doi-asserted-by":"publisher","first-page":"27207","DOI":"10.1074\/jbc.M101024200","volume":"276","author":"A Quintas","year":"2001","unstructured":"Quintas\u00a0A, Vaz\u00a0DC, Cardoso\u00a0I, Saraiva\u00a0MJ, Brito\u00a0RM (2001) Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J\u00a0Biol Chem 276(29):27207\u201327213","journal-title":"J Biol Chem"},{"issue":"7","key":"1288_CR26","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","volume":"34","author":"C Rapezzi","year":"2013","unstructured":"Rapezzi\u00a0C, Quarta\u00a0CC, Obici\u00a0L, Perfetto\u00a0F, Longhi\u00a0S, Salvi\u00a0F, Biagini\u00a0E, Lorenzini\u00a0M, Grigioni\u00a0F, Leone\u00a0O, Cappelli\u00a0F, Palladini\u00a0G, Rimessi\u00a0P, Ferlini\u00a0A, Arpesella\u00a0G, Pinna\u00a0AD, Merlini\u00a0G, Perlini\u00a0S (2013) Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart\u00a0J 34(7):520\u2013528","journal-title":"Eur Heart J"},{"issue":"5","key":"1288_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s42451-020-00184-8","volume":"3","author":"M Schilling","year":"2020","unstructured":"Schilling\u00a0M, Auer-Grumbach\u00a0M, Baron\u00a0R, Birklein\u00a0F, Escolano-Lozano\u00a0F, Dohrn\u00a0MF, Geber\u00a0C, Grether\u00a0N, Hagenacker\u00a0T, Hahn\u00a0K, Lehmann\u00a0HC, Sachau\u00a0J, Schmidt\u00a0J, Schulte-Mattler\u00a0W, Sommer\u00a0C, Weiler\u00a0M, Hund\u00a0E (2020) Heredit\u00e4re Transthyretinamyloidose (ATTRv-Amyloidose). DGNeurologie 3(5):369\u2013383","journal-title":"DGNeurologie"},{"issue":"1","key":"1288_CR28","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1080\/07853890.2021.1988696","volume":"53","author":"V Skrahina","year":"2021","unstructured":"Skrahina\u00a0V, Grittner\u00a0U, Beetz\u00a0C, Skripuletz\u00a0T, Juenemann\u00a0M, Kr\u00e4mer\u00a0HH, Hahn\u00a0K, Rieth\u00a0A, Schaechinger\u00a0V, Patten\u00a0M, Tanislav\u00a0C, Achenbach\u00a0S, Assmus\u00a0B, Knebel\u00a0F, Gingele\u00a0S, Skrahin\u00a0A, Hartkamp\u00a0J, F\u00f6rster\u00a0TM, Roesner\u00a0S, Pereira\u00a0C, Rolfs\u00a0A (2021) Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology. Ann Med 53(1):1787\u20131796","journal-title":"Ann Med"},{"issue":"4","key":"1288_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon\u00a0SD, Adams\u00a0D, Kristen\u00a0A, Grogan\u00a0M, Gonz\u00e1lez-Duarte\u00a0A, Maurer\u00a0MS, Merlini\u00a0G, Damy\u00a0T, Slama\u00a0MS, Brannagan\u00a0TH 3rd, Dispenzieri\u00a0A, Berk\u00a0JL, Shah\u00a0AM, Garg\u00a0P, Vaishnaw\u00a0A, Karsten\u00a0V, Chen\u00a0J, Gollob\u00a0J, Vest\u00a0J, Suhr\u00a0O (2019) Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 139(4):431\u2013443","journal-title":"Circulation"},{"issue":"2","key":"1288_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/13506129.2020.1855134","volume":"28","author":"MN Ungerer","year":"2021","unstructured":"Ungerer\u00a0MN, Hund\u00a0E, Purrucker\u00a0JC, Huber\u00a0L, Kimmich\u00a0C, Aus dem Siepen\u00a0F, Hein\u00a0S, Kristen\u00a0AV, Hinderhofer\u00a0K, Kollmer\u00a0J, Sch\u00f6nland\u00a0S, Hegenbart\u00a0U, Weiler\u00a0M (2021) Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a\u00a020-year German single-referral centre experience. Amyloid 28(2):91\u201399","journal-title":"Amyloid"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-022-01288-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-022-01288-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-022-01288-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T14:05:34Z","timestamp":1655301934000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-022-01288-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,13]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1288"],"URL":"https:\/\/doi.org\/10.1007\/s00115-022-01288-0","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,13]]},"assertion":[{"value":"8 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Schilling hat von den Firmen Akcea, Alnylam und Pfizer Honorare f\u00fcr Vortrags- und Beratungst\u00e4tigkeiten inkl. Reisekosten erhalten.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}